AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21835316 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt revascularization
Number of subjects: 2368
Study 21835316 — intervention group
Group type: COMPARATOR
Intervention: Initial medical therapy with deferred revascularization
Number of subjects: 2368
Study 21835316 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin sensitization
Number of subjects: 2368
Study 21835316 — intervention group
Group type: COMPARATOR
Intervention: Insulin provision
Number of subjects: 2368
Study 21835316 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 2368
Study 20183450 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean cumulative function (MCF) approach for analyzing adverse events data
Number of subjects: 0
Study 20183450 — intervention group
Group type: COMPARATOR
Intervention: Crude incidence rates
Number of subjects: 0
Study 20183450 — intervention group
Group type: COMPARATOR
Intervention: Exposure-adjusted incidence rates
Number of subjects: 0
Study 17124897 — intervention group
Group type: EXPERIMENTAL
Intervention: WaveLight Allegretto Wavefront-Optimized system
Number of subjects: 14
Study 17124897 — intervention group
Group type: COMPARATOR
Intervention: Alcon CustomCornea system
Number of subjects: 14
Study 15005471 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based oral health education programme
Number of subjects: 803
Study 11439393 — intervention group
Group type: EXPERIMENTAL
Intervention: Tractor work assignment
Number of subjects: 1138
Study 11439393 — intervention group
Group type: COMPARATOR
Intervention: NAGCAT recommendations
Number of subjects: 1138
Study 9175404 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 6595
Study 9175404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6595
Study 1606095 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg flunitrazepam
Number of subjects: 80
Study 1606095 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg lorazepam
Number of subjects: 80
Study 1606095 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg midazolam
Number of subjects: 80
Study 1606095 — intervention group
Group type: COMPARATOR
Intervention: No premedication (control group)
Number of subjects: 80
Study 1606095 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall premedicated patients
Number of subjects: 80
Study 3914860 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine chemoprophylaxis
Number of subjects: 198
Study 3914860 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 198
Study 30823411 — intervention group
Group type: EXPERIMENTAL
Intervention: CGMP‐AA and usual dietary Phe (R1)
Number of subjects: 19
Study 30823411 — intervention group
Group type: EXPERIMENTAL
Intervention: CGMP‐AA − Phe content of CGMP‐AA from usual diet (R2)
Number of subjects: 19
Study 30823411 — intervention group
Group type: COMPARATOR
Intervention: L‐AA and usual dietary Phe (R3)
Number of subjects: 19
Study 28434271 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen washout procedure after intubation
Number of subjects: 24
Study 28434271 — intervention group
Group type: COMPARATOR
Intervention: Control group (no oxygen washout)
Number of subjects: 24
Study 25844821 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (treated poor metabolizers)
Number of subjects: 0
Study 25844821 — intervention group
Group type: COMPARATOR
Intervention: Placebo (treated children)
Number of subjects: 0
Study 25844821 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (treated extensive metabolizers)
Number of subjects: 0
Study 23474701 — intervention group
Group type: EXPERIMENTAL
Intervention: Subliminal activation of implicit unfairness
Number of subjects: 0
Study 23474701 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 21851299 — intervention group
Group type: EXPERIMENTAL
Intervention: Infected with 1.5 x 10^9 cfu M. haemolytica in 5 mL sterile nutrient broth
Number of subjects: 20
Study 21851299 — intervention group
Group type: COMPARATOR
Intervention: Control group inoculated with 5 mL sterile nutrient broth
Number of subjects: 20
Study 17853034 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D stereologic technique
Number of subjects: 15
Study 17853034 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LUTS)
Number of subjects: 15
Study 16965682 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (made in Beijing) 75 mg/m² plus cisplatin 70 mg/m²
Number of subjects: 77
Study 16965682 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (made in Jiangsu) 75 mg/m² plus cisplatin 70 mg/m²
Number of subjects: 77
Study 12767735 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate therapy
Number of subjects: 0
Study 12767735 — intervention group
Group type: COMPARATOR
Intervention: Standard haemodialysis treatment
Number of subjects: 0
Study 10867427 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% chlorhexidine varnish (EC40) after dental treatment
Number of subjects: 23
Study 10867427 — intervention group
Group type: COMPARATOR
Intervention: Full dental treatment only
Number of subjects: 23
Study 8637402 — intervention group
Group type: EXPERIMENTAL
Intervention: Melanotan-II (MT-II) at doses of 0.01 mg/kg, escalated to 0.025 mg/kg and 0.03 mg/kg
Number of subjects: 3
Study 8637402 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 3
Study 1595533 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (n = 14)
Number of subjects: 32
Study 1595533 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (n = 11)
Number of subjects: 32
Study 1595533 — intervention group
Group type: COMPARATOR
Intervention: Adenosine
Number of subjects: 32
Study 1595533 — intervention group
Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 32
Study 3927332 — intervention group
Group type: EXPERIMENTAL
Intervention: Pizotifene (4 mg daily for 3 days orally)
Number of subjects: 18
Study 3927332 — intervention group
Group type: COMPARATOR
Intervention: Naloxone-HCI (0.8 mg intravenously)
Number of subjects: 18
Study 3927332 — intervention group
Group type: COMPARATOR
Intervention: No drug treatment (control group)
Number of subjects: 18
Study 3771853 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% tretinoin cream
Number of subjects: 0
Study 3771853 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 0
Study 31823403 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized model (model-P)
Number of subjects: 266
Study 31823403 — intervention group
Group type: COMPARATOR
Intervention: Baseline model (model-B)
Number of subjects: 266
Study 31823403 — intervention group
Group type: COMPARATOR
Intervention: Clinical experts
Number of subjects: 266
Study 29871618 — intervention group
Group type: EXPERIMENTAL
Intervention: Health check intervention
Number of subjects: 98
Study 28794206 — intervention group
Group type: COMPARATOR
Intervention: Iron and folic acid capsule (IFA) daily from ≤20 wk gestation until delivery, followed by placebo daily from delivery to 6 mo postpartum
Number of subjects: 647
Study 28794206 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNS) daily from ≤20 wk gestation to 6 mo postpartum
Number of subjects: 647
Study 28794206 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient (MMN) capsule daily from ≤20 wk gestation to 6 mo postpartum
Number of subjects: 647
Study 26211828 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine-guided ablation
Number of subjects: 534
Study 26211828 — intervention group
Group type: COMPARATOR
Intervention: No further ablation (Control)
Number of subjects: 534
Study 26211828 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without dormant pulmonary vein conduction
Number of subjects: 534
Study 24072231 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-ifosfamide-cisplatin (TIP) chemotherapy
Number of subjects: 32
Study 20495502 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy (hemoglobin of < 9.0 g/dL)
Number of subjects: 60
Study 20495502 — intervention group
Group type: COMPARATOR
Intervention: Liberal transfusion strategy (hemoglobin of ≥ 13.0 g/dL)
Number of subjects: 60
Study 19118735 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical bypass for infrainguinal disease (specific intervention details not provided)
Number of subjects: 2110
Study 19118735 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk stratification model based on predictors (dialysis, tissue loss, age >or=75, hematocrit <or=30, advanced CAD)
Number of subjects: 2110
Study 17162997 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep session
Number of subjects: 13
Study 17162997 — intervention group
Group type: COMPARATOR
Intervention: Daytime wake session
Number of subjects: 13
Study 14602771 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/d)
Number of subjects: 67
Study 14602771 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate (800 mg/d)
Number of subjects: 67
Study 14602771 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (400 IU/d) in simvastatin-treated patients
Number of subjects: 67
Study 14602771 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (400 IU/d) in bezafibrate-treated patients
Number of subjects: 67
Study 10927732 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led anticoagulation clinic with near-patient testing and computerized decision support software
Number of subjects: 367
Study 10927732 — intervention group
Group type: COMPARATOR
Intervention: Routine hospital management (control)
Number of subjects: 367
Study 8881624 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltanolone 0.75 mg kg‐1
Number of subjects: 76
Study 8881624 — intervention group
Group type: COMPARATOR
Intervention: Propofol 2.5 mg kg‐1
Number of subjects: 76
Study 8881624 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone 4 mg kg‐1
Number of subjects: 76
Study 15278580 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg.kg(‐1) vecuronium (low dose group)
Number of subjects: 18
Study 15278580 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.20 mg.kg(‐1) vecuronium (high dose group)
Number of subjects: 18
Study 6375469 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine (5 mg t.i.d.)
Number of subjects: 31
Study 6375469 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400 mg t.i.d.)
Number of subjects: 31
Study 6375469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 6375469 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine and Pentoxifylline
Number of subjects: 31
Study 6375469 — intervention group
Group type: COMPARATOR
Intervention: Placebo, Flunarizine, Pentoxifylline
Number of subjects: 31
Study 30791950 — intervention group
Group type: EXPERIMENTAL
Intervention: Scenarios labeled as 'cancer'
Number of subjects: 167
Study 30791950 — intervention group
Group type: COMPARATOR
Intervention: Scenarios labeled as 'serious illness' (Control)
Number of subjects: 167
Study 30791950 — intervention group
Group type: EXPERIMENTAL
Intervention: Scenarios labeled as 'cancer' (more serious scenarios)
Number of subjects: 167
Study 28212390 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish Oil (FO) supplementation (2 g/d EPA and 1 g/d DHA)
Number of subjects: 26
Study 28212390 — intervention group
Group type: COMPARATOR
Intervention: Olive Oil (OO) control (3 g/d)
Number of subjects: 26
Study 28212390 — intervention group
Group type: EXPERIMENTAL
Intervention: Both FO and OO groups pooled
Number of subjects: 26
Study 25443593 — intervention group
Group type: EXPERIMENTAL
Intervention: SHARP program (Staying Healthy‐Asthma Responsible and Prepared™)
Number of subjects: 205
Study 25443593 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 205
Study 23680248 — intervention group
Group type: EXPERIMENTAL
Intervention: High SES group
Number of subjects: 100
Study 23680248 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 100
Study 21375784 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung cancer screening (intervention group)
Number of subjects: 0
Study 21375784 — intervention group
Group type: COMPARATOR
Intervention: No screening (control group)
Number of subjects: 0
Study 19415504 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivorship care plans (SCP)
Number of subjects: 20
Study 19415504 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care and psychosocial elements
Number of subjects: 20
Study 19415504 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion and preparation of SCP
Number of subjects: 20
Study 17979579 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) at a mean dose of 14.22 mg/day, n = 63
Number of subjects: 114
Study 17979579 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL), n = 51
Number of subjects: 114
Study 15006914 — intervention group
Group type: EXPERIMENTAL
Intervention: Yeast-based tablet with selenium
Number of subjects: 0
Study 15006914 — intervention group
Group type: COMPARATOR
Intervention: Yeast-based tablet without selenium
Number of subjects: 0
Study 11431613 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour postprandial plasma glucose screening test
Number of subjects: 100
Study 11431613 — intervention group
Group type: COMPARATOR
Intervention: 1-hour 50 gm plasma glucose test screening test
Number of subjects: 100
Study 9537619 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lipid emulsion containing 154 microg phylloquinone
Number of subjects: 12
Study 9537619 — intervention group
Group type: COMPARATOR
Intervention: Saline solution containing 154 microg phylloquinone
Number of subjects: 12
Study 8124970 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective decontamination therapy (oral and enteral selective decontamination with amphotericin B, polymyxin E, and tobramycin)
Number of subjects: 72
Study 8124970 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral paste and enteral solution)
Number of subjects: 72
Study 2510285 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil 300 micrograms
Number of subjects: 33
Study 2510285 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil 600 micrograms
Number of subjects: 33
Study 2510285 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil 150 micrograms
Number of subjects: 33
Study 2510285 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil 25 micrograms
Number of subjects: 33
Study 2510285 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil 50 micrograms
Number of subjects: 33
Study 2510285 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil 200 micrograms
Number of subjects: 33
Study 350904 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine gluconate mouthwash
Number of subjects: 0
Study 350904 — intervention group
Group type: COMPARATOR
Intervention: 0.5% astringent solution mouthwash
Number of subjects: 0
Study 350904 — intervention group
Group type: COMPARATOR
Intervention: Control mouthwash
Number of subjects: 0
Study 350904 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine gluconate gel
Number of subjects: 0
Study 350904 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 0
Study 31530655 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroform stent (NEU)
Number of subjects: 659
Study 31530655 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterprise stent (EP)
Number of subjects: 659
Study 31530655 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-profile Visualized Intraluminal Support stent (LVIS)
Number of subjects: 659
Study 31530655 — intervention group
Group type: COMPARATOR
Intervention: Intra-procedural complications
Number of subjects: 659
Study 31530655 — intervention group
Group type: COMPARATOR
Intervention: Post-procedural complications
Number of subjects: 659
Study 31530655 — intervention group
Group type: COMPARATOR
Intervention: Braided-stents vs laser-cut stents
Number of subjects: 659
Study 31149935 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention not specified
Number of subjects: 617
Study 28116974 — intervention group
Group type: EXPERIMENTAL
Intervention: Original indications (19 drugs, 31 studies)
Number of subjects: 299
Study 28116974 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental indications (18 drugs, 33 studies)
Number of subjects: 299
Study 28116974 — intervention group
Group type: EXPERIMENTAL
Intervention: All indications
Number of subjects: 299
Study 25561293 — intervention group
Group type: EXPERIMENTAL
Intervention: 25‐Hydroxyvitamin‐D (25‐VD3) levels in CRSwNP patients
Number of subjects: 57
Study 25561293 — intervention group
Group type: EXPERIMENTAL
Intervention: 25‐Hydroxyvitamin‐D (25‐VD3) levels in CRSsNP patients
Number of subjects: 57
Study 25561293 — intervention group
Group type: COMPARATOR
Intervention: Control group (noninflammatory pathology)
Number of subjects: 57
Study 22820813 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational cartoon story
Number of subjects: 120
Study 22820813 — intervention group
Group type: EXPERIMENTAL
Intervention: Reward calendar
Number of subjects: 120
Study 22820813 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent information leaflet
Number of subjects: 120
Study 22820813 — intervention group
Group type: COMPARATOR
Intervention: Control group (picture to color)
Number of subjects: 120
Study 21114527 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly hydrolysed formula
Number of subjects: 240
Study 21114527 — intervention group
Group type: COMPARATOR
Intervention: Cow's milk-based formula
Number of subjects: 240
Study 21114527 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrolysed formula
Number of subjects: 240
Study 19164422 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0
Study 19164422 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol tartrate
Number of subjects: 0
Study 19164422 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol vs. Metoprolol tartrate
Number of subjects: 0
Study 16704735 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL) - 6-dose course (20/120 mg tablets) over three days
Number of subjects: 119
Study 16704735 — intervention group
Group type: COMPARATOR
Intervention: Artesunate plus amodiaquine (AAMQ) - 3-day course (4 mg/kg artesunate and 10 mg/kg amodiaquine)
Number of subjects: 119
Study 14992881 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (80 mg/kg ideal weight preoperatively and 8 mg/kg ideal weight IV per hour for 48 hours)
Number of subjects: 202
Study 14992881 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation
Number of subjects: 202
Study 14992881 — intervention group
Group type: COMPARATOR
Intervention: Control (dextrose 5% water)
Number of subjects: 202
Study 11381810 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuff pressure equal to or less than 42 mmHg (Group A)
Number of subjects: 40
Study 11381810 — intervention group
Group type: COMPARATOR
Intervention: Cuff pressure higher than 42 mmHg (Group B)
Number of subjects: 40
Study 11381810 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 40
Study 11381810 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuff pressure
Number of subjects: 40
Study 9154884 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime (two 1,500 mg doses 12 hours apart after intubation)
Number of subjects: 100
Study 9154884 — intervention group
Group type: COMPARATOR
Intervention: Control (no cefuroxime, 17 patients received prophylactic antibiotics)
Number of subjects: 100
Study 9154884 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime
Number of subjects: 100
Study 9154884 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 100
Study 9154884 — intervention group
Group type: COMPARATOR
Intervention: Control (patients receiving prior antibiotics)
Number of subjects: 100
Study 9154884 — intervention group
Group type: COMPARATOR
Intervention: Control (patients not receiving prior antibiotics)
Number of subjects: 100
Study 9154884 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime and/or prior antibiotics in control group
Number of subjects: 100
Study 9154884 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with pneumonia (both groups)
Number of subjects: 100
Study 7835794 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel/cisplatin
Number of subjects: 0
Study 7835794 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel (24-hr infusion)
Number of subjects: 0
Study 7835794 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 0
Study 3322670 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐propranolol (Obsidan)
Number of subjects: 22
Study 3322670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 29944874 — intervention group
Group type: EXPERIMENTAL
Intervention: C-arm-guided reduction
Number of subjects: 20
Study 29944874 — intervention group
Group type: COMPARATOR
Intervention: Control group (palpation, auditory cues, visualization of symmetry)
Number of subjects: 20
Study 29944874 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (C-arm and control)
Number of subjects: 20
Study 28643733 — intervention group
Group type: EXPERIMENTAL
Intervention: Gem/Cis (Cisplatin 40 mg/m2 on day 1 and day 8 combined with Gemcitabine 1000 mg/m2 on day 1 and day 8)
Number of subjects: 71
Study 28643733 — intervention group
Group type: COMPARATOR
Intervention: Gem/Carb (Carboplatin AUC 5 on day 1 combined with Gemcitabine 1000 mg/m2 on day 1 and day 8)
Number of subjects: 71
Study 28643733 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 71
Study 25909369 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% sodium cromoglicate emulsion
Number of subjects: 177
Study 25909369 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 177
Study 22983820 — intervention group
Group type: EXPERIMENTAL
Intervention: Music Therapy (MT) added to Standard Care (SC)
Number of subjects: 79
Study 22983820 — intervention group
Group type: EXPERIMENTAL
Intervention: Music Therapy (MT)
Number of subjects: 79
Study 22983820 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 79
Study 20370452 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin applied once weekly (Group I)
Number of subjects: 33
Study 20370452 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin applied three times weekly (Group II)
Number of subjects: 33
Study 20370452 — intervention group
Group type: COMPARATOR
Intervention: Prior to mupirocin treatment
Number of subjects: 33